Mannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency
Authors:
Open Access
- 17 January 2024
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 32 (1) , 101187
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- ANR
This publication has 41 references indexed in Scilit:
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- Biodistribution and Shedding of AAV Vectors2011
- Dosage Thresholds for AAV2 and AAV8 Photoreceptor Gene Therapy in MonkeyScience Translational Medicine, 2011
- Novel Properties of Tyrosine-mutant AAV2 Vectors in the Mouse RetinaMolecular Therapy, 2011
- High-efficiency Transduction of the Mouse Retina by Tyrosine-mutant AAV Serotype VectorsMolecular Therapy, 2009
- Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower dosesProceedings of the National Academy of Sciences, 2008
- Mannose–pepstatin conjugates as targeted inhibitors of antigen processingOrganic & Biomolecular Chemistry, 2006
- Evaluation of concanavalin A–mannose interaction on the electrode covered with collagen filmTalanta, 2006
- Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulationMolecular Therapy, 2005
- Biodistribution of rAAV Vectors Following Intraocular Administration: Evidence for the Presence and Persistence of Vector DNA in the Optic Nerve and in the BrainMolecular Therapy, 2005